Trial launches of diagnostic agent for clear cell renal cell carcinoma
The future of OAB treatment: Emerging nerve targets and AI may guide therapy
FDA expands Illuccix label to include patient selection for RLT in pre-taxane setting
FDA greenlights phase 1 trial of theranostic radiopharmaceutical for mCRPC
